美银-中国医疗健康:AIDD 101:从更智能模型到临床验证_第1页
美银-中国医疗健康:AIDD 101:从更智能模型到临床验证_第2页
美银-中国医疗健康:AIDD 101:从更智能模型到临床验证_第3页
美银-中国医疗健康:AIDD 101:从更智能模型到临床验证_第4页
美银-中国医疗健康:AIDD 101:从更智能模型到临床验证_第5页
已阅读5页,还剩47页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Accessibleversion

BofAGLOBALRESEARCH

BofASECURIES

ChinaHealthcare

AIDD101:fromsmartermodelstoclinicalvalidation

IndustryOverview

Al-drivendrugdiscoverygainsmomentum

Al-drivendrugdiscoveryanddevelopment(AIDD)ismovingfromtechnologicalpromisetowardclinicalvalidation.Weseegrowinginvestorinterest,drivenby:1)globallarge

languagemodel(LLM)leadersextendingtheircapabilitiesintodrugdiscovery;2)Al-

generatedcandidatesadvancingthroughclinicaldevelopment;and3)expanding

partnershipswithlargepharma.Webelieveaccumulatingclinicalevidencecouldsupportbroaderindustryadoptionbydemonstratingimprovementsindrugquality,developmenttime,andcost.Together,thesedevelopmentscouldaccelerateAIDDadoptionacross

pharmaceuticalR&D.ThisreportoutlinestheAIDDworkflow,competitivelandscape,andbusinessmodels,andprovidesaframeworkforassessingChina'semergingplayers.

Fasterdiscoverywithlowerexperimentalburden

Alcananalyzebiologicaldatatoprioritizetargets,generatenovelmoleculesandassesspotency,selectivity,anddevelopabilitysimultaneously.Computationalscreeningcaneliminateunsuitablecompoundsbeforesynthesis,reducingthenumberofmoleculesresearchersneedtosynthesizeandtest.Aloffersitsgreatesttimesavingsbetweentargetdiscoveryandpreclinicalcandidate(PCC)nomination,whereithelps

researchersdesign,screenandselectmoleculesfaster.Insilicoreportstarget-to-PCCtimelinesof12-18monthsvs.morethan54monthsunderitstraditionalbenchmark.BeyondPCCnomination,Alcouldmainlysupportdataanalysis,whilemandatorysafetystudies,clinicaltrials,andregulatoryreviewstilltaketimeandarehardertoshorten.

Experimentaldataandclinicalprogressgiveleadersanedge

WebelieveearlyAIDDleadersbenefitfromexperimentaldataandclinicalresultsthat

betteralgorithmsalonecannotreproduce.Theirdrylabsdesignmolecules,andtheirwetlabssynthesizeandtestthem,feedingtheresultsbackintothenextdesigncycle.Dataonwhichmoleculesworked,whichfailed,andunderwhattestingconditionscanhelpguidefuturecandidateselection.Newentrantsmusteitherobtaincomparabledataorspendtimeandresourcesgeneratingitexperimentally.Clinical-stageassetsprovideanotherheadstart,asearlymovershavealreadybeguncollectinghumansafety,dose,andefficacydata.Bettermodelsmayacceleratediscovery,butpatientrecruitment,treatment,andfollow-upstilltaketime,whichhelpsestablishedplayersretaintheirclinicallead.

Favorassetownership;BuyInsilico,IAM,andSDGR

WefavorAIDDcompaniesthatowntheirdrugcandidatesandretainrightstolicensingpaymentsandfuturedrugsales.Aclinicallydifferentiated,patent-protecteddrugcan

remainvaluableevenasnewerAlmodelsemerge.WeinitiatecoverageofInsilicoatBuy(seeourreport.InsilicoMedicineCavmanTopco:Bevondinsilico:pivotalphaseahead).supportedbyassetownership,scientist-guidedAldiscovery,andvalidationfrompharmapartnerships.WealsorateIAMBuyforitsAl-drivenmoleculardesigncapabilitiesand

earlyclinicalvalidationfromIAM1363,andSDGRBuyforitsdifferentiated

computationalplatformfordiscoveringanddevelopingadvancedcompounds.

>>Employedbyanon-USaffiliateofBofASandisnotregistered/qualifiedasaresearchanalystundertheFINRArules.

Referto"OtherImportantDisclosures"forinformationoncertainBofASecuritiesentitiesthattakeresponsibilityfortheinformationhereininparticularjurisdictions.

BofASecuritiesdoesandseekstodobusinesswithissuerscoveredinitsresearch

reports.Asaresult,investorsshouldbeawarethatthefirmmayhaveaconflictof

interestthatcouldaffecttheobjectivityofthisreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.

Refertoimportantdisclosuresonpage24to27.AnalystCertificationonpage19.Price

ObjectiveBasis/Riskonpage17.13044271

13November2026

Equity

China

Healthcare

DavidLi>>

ResearchAnalyst

+85235084531

MerrillLynch(HongKong)

davidbo.li@

SandraSun>>ResearchAnalyst

MerrillLynch(HongKong)

sandra.sun@

AlecW.Stranahan

ResearchAnalystBofAS

alec.stranahan@

LuLi

ResearchAnalystBofAS

lu.li5@bofa.com

EthanCui>>

ResearchAnalyst

MerrillLynch(HongKong)

ethan.cui@

AIDD:Al-drivendrugdiscoveryanddevelopment

BD:businessdevelopmentIAM:lambic

LLM:Largelanguagemodel

PCC:PreclinicalcandidateSDGR:Schrodinger

Seepage17foraglossaryofadditionalterms.

BofAGLOBALRESEARCH

Aldrugdiscovery101

Alreshapingdrugdiscoveryindustry

AlisincreasinglyappliedacrosspharmaceuticalR&D,fromdiseaseunderstandingandtargetidentificationtomoleculardesign,preclinicalevaluation,andclinical-trial

optimization.Byintegratinglarge,complexdatasets,Alcanimprovehypothesisgeneration,expandthesearchablechemicalspace,andsupportmoredata-drivendevelopmentdecisions.

WebelieveAl-drivendrugdiscoveryanddevelopment(AIDD)hasthepotentialto

improvepharmaceuticalR&Dproductivitythroughthreechannels.Thefirstisfaster

discovery:Alcananalyzebiologicaldata,prioritizetargets,andoptimizemoleculesmorerapidlythantraditionalsequentialworkflows.Thesecondisalowerexperimentalburden,ascomputationalscreeningcaneliminateunsuitablemoleculesbeforesynthesis.The

thirdisbetterdevelopmentdecisions,asAlcansupportcandidateselection,translationalmodeling,patientstratification,andclinical-trialdesign.

However,AI'simpactisnotevenlydistributedacrossthedevelopmentlifecycle.The

greatestdirecttimesavingsliebetweentargetdiscoveryandpreclinicalcandidate(PCC)nomination,wherecomputationandautomationcanacceleraterepeateddesign-and-

testcycles.AfterPCCnomination,developmentisincreasinglyconstrainedbymandatorytoxicologystudies,clinicalobservationperiods,manufacturingrequirements,and

regulatoryreview.

Exhibit1:Alindrugdiscovery:workflow,contributions,andkeyAIDDplayers

Fromtargettopatients

Drug

discoverystages

1.Diseaseunderstanding

&targetdiscovery

2.Target-to-hit

3.Hit-to-lead

4.Leadoptimization

P

Precl

Cand

CC

inicalidate

5.Preclinical

development

6.Clinicaldevelopment

andbeyond

ldentifydiseasemechanisms

andvalidatetarget(s)

Findinitialactive

molecules(hits)

%

Optimizehitseriesintoleadcompounds

Improvepotency,selectivity,ADMETanddevelopability

IND-enablingstudies

(safety,PK/PD,toxicology,

manufacturing)

PhaseI-II,regulatory

approvaland

commercialization

HowAlhelps

·Integratemulti-omics,

clinicaldataandliterature

·Prioritizenoveltargets

·Explorenewindicationsforexistingtargets

(target-to-indication)

·Virtualscreeningand

generativedesign

·Predictbindingandkeyproperties

·Prioritizemolecules

forsynthesisandtesting

·Suggeststructuralmodifications

·Predictactivity,selectivity,ADMETandsyntheticfeasibility

●Balancemultiplepropertieswithiterativedesign

·Multi-parameteroptimizationwithexperimentalfeedback

·Predictsyntheticroutes

·PrioritizecandidatesforPCC(e.g,~60-200vs.~1,000

underconventionalbenchmark)

·Predictselected

safetyrisks

·PK/PDmodeling

·FormulationandCMCsupport

·Patientstratification

·Trialdesignandsiteselection

·Clinicalandreal-worlddataanalysis

●Regulatorydocumentpreparationsupport

Key

players

androles

Insilico

Medicine

Al-driven,asset-leddrugdiscoverywithproprietarypipelineand

softwarebusiness

Businessmodel/valuecapture

·Retainedpipeline(eg.,rentosertib,ISMprograms)

·Out-licensing&co-development

·Softwaresubscriptions(Pharma.Alplatform)

PandaOmicsChemistry42

(targetdiscovery&indicationproritization)(hitdiscovery,hit-to-leadandleadoptimization)

XXtalPi

Alandrobotics-enableddiscovery

solutionsforpharma/biotech,

withpartneredandproprietary

pipelines

Al-powereddiscoverysolutionsAutomatedsynthesisandtesting

(targetdiscovery,moleculedesign,propertyprediction)(A¹4Sroboticlaboratories)lterativedesign-make-test-analyze

·Partnerprograms(withpharma/biotech,e.g.SIGX1094,RTX-117,PEP08)

·Proprietarypipeline(eg,XTN004,ALX001/002/005)

·Al4Sinfrastructureandservices

(roboticlaboratoriesanddrugdiscoverysolutions)

Al-designedprotein/antibody

forsynthesisandtesting

sequences

Experimentalresults

formodelrefinement

andAl-readydata

andnext-rounddesign

GenScript

MakeResearchEasy

ExperimentalservicestosupportAl-designedproteinsandantibodies

Wet-abvalidationservices(primarilyforbiologics:proteins,antibodies,etc.)

·Contractresearchservices

·High-throughputvalidation

·Al-readydataformodeltraining

凸

Proteinexpression

andpurification

Al-readydata

(standardized,high-quality)

Genesynthesis

andconstructpreparation

D冒

Assaydevelopment→址

andfunctionaltesting

Design→Make→Test→Analyze→Learn→Redesign

Acontinuousdry-wetlabcycleacrossearlydiscovery

Source:BofAGlobalResearch

BofAGLOBALRESEARCH

2

ChinaHealthcare|13November2026

WhatisAI-baseddrugdiscovery

AIDDreferstotheuseofmachinelearning,generativemodels,foundationmodels,andautomatedworkflowsacrosspharmaceuticalresearchanddevelopment.Itshouldnotbeunderstoodasasinglealgorithmautonomouslyproducingamedicine.Drugdiscovery

involvesalargenumberofinterdependentbiological,chemical,experimental,and

operationaldecisions,andtheprocessmayencompassmorethan1,000computationaltasksandskills.

ThevalueofanAIDDplatformthereforedependsonmorethantheperformanceofanindividualmodel.Acommerciallyrelevantplatformmustidentifybiologicallymeaningfulandcommerciallyattractivetargets.Itmustgeneratemoleculeswithacceptable

potency,selectivity,andsafety,validatepredictionsexperimentally,andadvanceselectedcandidatesthroughformaldevelopment.Itmustalsodeterminewhichmodelstouse,howmuchconfidencetoplaceintheiroutputs,andwhen

additionalphysicalexperimentsarerequired.

Exhibit2:AIapplicationsacrossthedrugdiscoveryanddevelopmentworkflow

AIimprovesefficiencyfromtargetdiscoverytoclinicaldevelopmentthroughdata-drivenpredictionandoptimization.

Application

WhatAIenables

Illustrativeexample

Targetdiscovery

Enabledrugdiscoverybyidentifyingandvalidatingnewtargets.

AImodelscananalyzelargedatasetstopinpointproteinsorpathways,generatingnewtargetsforintervention.

Moleculedesign

Supportdrugdesignbygeneratingmolecularstructuresoptimizedforspecificproperties.

Generativemodelscanproposemolecules

optimizedforpotency,selectivityandbioavailability.

Clinicaltrials

ptimizeclinicaltrialsbyidentifying

patientsubgroupslikelytorespondtoaparticulartreatment.

Modelscanidentifypredictivegeneticmarkersassociatedwithtreatmentresponse.

Source:LiteratureReview,Frost&SullivanAnalysis,BofAGlobalResearch

BofAGLBALRESEARCH

HowAIisappliedacrossdrugdiscoveryanddevelopmentTargetdiscovery:findingnewdiseaseinterventionpoints

Targetdiscoveryseekstoidentifyaprotein,gene,orbiologicalpathwaythatcanbe

modulatedtotreatadisease.Conventionaltargetdiscoveryreliesonscientificliterature,individualdatasets,andexperimentalbiology.AIcanintegrateabroaderrangeof

information,incl.genomic,transcriptomic,proteomic,single-cell,disease-network,clinical,patent,andscientific-literaturedata.Indoingso,itcanpotentiallyidentifyrelationshipsthataredifficulttodetectthroughconventionalhypothesis-ledresearchalone.

Ausefultarget-discoveryplatformmustdomorethanretrieveandsummarizeexistinginformation.Itmustranktargetsbyhumandiseaseevidence,biologicalrelevance,causalsupport,druggability,potentialefficacy,safetyimplications,competitiveintensity,andbiomarkeravailability.Insilico’sPandamicsillustratesthisapproachbyintegrating

multi-omicsandotherbiologicaldatatoidentifyandprioritizepotentialtherapeutic

targets.Forrentosertib,Pandamicsanalyzedmulti-omics,single-cell,disease-networkandliteraturedatarelatedtoidiopathicpulmonaryfibrosis(IPF).Itthenprioritized

Traf2-andNck-interactingkinase(TNIK)asapotentialfibrosistargetatatimewhenTNIKwasnotyetwidelyestablishedasanIPFdrugtarget.

Moleculedesign:multi-objectiveoptimizationproblem

nceatargethasbeenselected,generativechemistrymodelscanproposenovel

chemicalstructuresandoptimizethemacrossmultipleparameters.Theobjectiveisnottogenerateasmanymoleculesaspossible.Instead,itistoidentifyalimitednumberofcandidatesthatbalancepotency,selectivity,solubility,tissueexposure,metabolic

stability,toxicity,syntheticaccessibility,patentability,formulationpotential,andmanufacturingfeasibility.

ChinaHealthcare|13November20263

4ChinaHealthcare|13November2026

Thesepropertiesareinterdependentandmayconflict.Astructuralmodificationthat

improvespotencymayreducesolubility,whileachangeintendedtoimproveexposure

mayintroducemetabolicoroff-targetliabilities.AI-enabledmoleculedesignisthereforeamulti-objectiveoptimizationprocessratherthanasimplestructure-generation

exercise.Generativemodelscanexploreabroaderchemicalspace,predictpotential

liabilities,andoptimizeseveralpropertiesinparallel,buttheresultingcompoundsmuststillbesynthesizedandvalidatedexperimentally.

Preclinicaldevelopment:identifyingfailurerisksearlier

Beforeacandidateentershumantrials,itmustundergopreclinicalevaluationto

determinewhetheritsefficacy,safety,exposureanddevelopabilityprofileisacceptable.AIcansupportthisprocessinseveralways.Theseincludepredictingabsorption,

distribution,metabolism,excretionandtoxicity(ADMET)anddrugmetabolismand

(DMPK).AIcanalsosupportoff-targetandtoxicityassessment,doseandexposuremodeling,synthetic-routeplanning,formulationanalysisandcandidateprioritization.

Identifyingweakcandidatesearliermaypreventresourcesfrombeingallocatedto

compoundsthatareunlikelytopassformalinvestigationalnewdrug(IND)-enabling

development.AIcanalsoidentifythemostinformativeexperimentsandhelpintegrateresultsacrossassays.Nevertheless,predictedpropertiesmustultimatelybeverifiedinbiochemical,cellularandanimalstudies.AIcandirectphysicalexperimentsmore

efficiently,butitdoesnoteliminatetheneedforthem.

Clinicaldevelopment:improvingdecisions,noteliminatingtimelines

AIapplicationsinclinicaldevelopmentincludebiomarkeridentification,patient

stratification,siteselection,patientmatching,protocoldesign,doseoptimization,trialmonitoringandoutcomeprediction.Modelscananalyzeelectronichealthrecords,

genomicinformationandhistoricaltrialdatatoidentifypatientpopulationsmorelikelytorespondtoatreatment.Thiscouldimproveenrollmentefficiencyandtheabilitytodetecttreatmenteffects.

urUSteam’sreportAIBasics:DrugDiscoveryalsohighlightedthedistinctionbetweenpredictingchemistryandmodelingcomplexbiology.Computationaltoolscanhelp

optimizemolecularproperties,buttranslatingtheseimprovementsintotherapeutic

benefitremainsaseparatechallenge.Better-designedmoleculesthereforestillrequireexperimentalandclinicalvalidation,andimproveddiscoveryefficiencyshouldnotbeequatedwithaprovenincreaseinclinicalsuccessrates.

AIDDcasestudy:TargetZinpain

InsilicodevelopedISM9528,apotentialfirst-in-class(FIC)small-moleculeinhibitorof

theundisclosedTargetZ,asanon-opioidanalgesicforpainmanagement.Insilico

approachedthediscoveryfromtwodirections:1)Startwiththedisease:whichbiologicaltargetsmighthelptreatpain?Pandamicsreviewedbiologicaldata,publishedresearchandotherevidencetoproduceatargetshortlist.2)Startwiththetarget:whichdiseasesmightbenefitfromadrugactingonthistarget?Pandamicscomparedthetarget

againstdatafromdifferentdiseasesandrankedthemostpromisingtreatment

opportunities.Whenthetwolistswerecompared,bothanalysespointedtoTargetZasapotentialtargetforpaintreatment.Thisgaveresearchersahypothesistotestrather

thanproofthatthetargetwouldwork.

Exhibit3:Insilico'sAl-poweredtargetidentificationforpain:TargetZ

Insilico'sAldiscoveryprocessforTargetZ

TargetZforPain

TargetIdentificationinPandaOmics

Models

OMICspanda'0mics

Diseaseof

Cross

Reference

IndicationRankinginPandaOmics

Listof

Indications

panda`Omics

Listof

Targets

Source:Insilico

BofAGLOBALRESEARCH

Next,Chemistry42helpedrefinethechemistryintoanorallyavailablecandidate.

Researchersmodeledthepossibleshapesofthetargetprotein,generatedmolecules,

andscreenedthemforintendedactivity,unwantedinteractionsandlikelybehaviorinthebody.Laboratorytestingprovidedfeedbackforfurtheroptimization,whichculminatedinISM9528.Themoleculeshowedsuperiorinvivoefficacycomparedwithmanycurrent

paintreatmentsandalsodemonstratedaverygoodsafetyprofile.

ChinaHealthcare|13November20265

BofAGLOBALRESEARCH

Exhibit4:Al-enabledcompoundgenerationandoptimization

InsilicouseChemistry42todesignthenovelmolecule

01Structureinput02Conformationmodel03Generation&selection

Generative

Chemistry

complexmodel

Compound/Scaffoldgeneration

Model

Training

Renerse-timeSDE(anrwne.drewiaa

P=民-G0G0kgPY疆+G9d'

Patentdata

extraction

AlchemistryADMET&Off-target

Filtration,clustering,scoring

04Experimentalfeedback

ExperimentalValidationSynthesis&Testing

·Bindingandfunctionalassay

·Bias/Safety/Toxic

·Developability/Liabilities

Proteinmodelconstruction

basedondiffusionmodelsand

Ontarget

binarymodel

Offtarget

binarymodel

homologyinformation

FomadSDEOnaiaive,cowiwa)

Multiple

conformation

Key

compound

Chemistry42

5ource:Insilico

BofAGLOBALRESEARCH

Al'sspeedadvantageisgreatestbeforePCCnomination

ThegreatestscopeforAl-drivenaccelerationliesbetweentargetdiscoveryandPCC

nomination.Thisperiodspansdisease-hypothesisgeneration,targetidentificationandvalidation,target-to-hitdiscovery,hit-to-leadprogression,leadoptimization,preliminaryADMETassessmentandfinalcandidateselection.Theseactivitiesinvolverepeated

cyclesofprediction,moleculedesign,synthesisandtesting,andtheycanincreasinglybeperformedcomputationallyandinparallel.

Alcanacceleratethesecyclesbyprioritizingtargets,exploringchemicalspaceand

eliminatingmoleculespredictedtobetoxic,unstableorotherwiseunsuitablebeforephysicalsynthesis.Laboratoryresourcescanthenbedirectedtowardasmallernumberofhigher-probabilitycompounds.Theearlydiscoverystageisthereforerelatively

compressiblethroughcomputation.

ThetimelinebecomesconsiderablylessflexibleafterPCCnomination.IND-enabling

toxicologystudiesrequiredefinedstudyandobservationperiods,whilechemistry,

manufacturingandcontrolsactivitiesrequirephysicalprocessdevelopmentandqualitytesting.PhaseItrialsgenerallyinvolvesequentialdoseescalationandsafetymonitoring.

PhasellandPhaseIIlstudiesdependonpatientrecruitment,treatmentduration,

endpointmeasurementandfollow-up,andregulatorysubmissionsremainsubjecttoformalreview.

6ChinaHealthcare|13November2026

BofAGLOBALRESEARCH

ChinaHealthcare|13November20267

Exhibit5:Drugdiscoveryprocessfromdiscoverytocommercial

AIDDcouldacceleratetheprocessbetweentargetdiscoverytoPCC,beyondPCCisheavilyregulatedandstandardizedtimeline.

SuperRegulated

DiseaseHypothesis

andTarget

Discovery*

PhaseⅢ

Usualytakesfrommonthstodecades.performedinacademicinstitutionsusinggovemmentfunds

Preclinical/Developmental(PCC/DC)

1-5% 1-10$0-1000

ProbabilityofSuccess%

Cycletime(years)

Costperlaunch

(capitalized).SMilions,2010data

54%

1.5

S273

75%

1.5

5166

34%

$319

70%

2.5

S314

Submission

tolaunch

Realworld

evidence

Territory

Candidate

optimization

Hitto-lead

Salesand

91%

85%

80%

S150

5414

S48

594

DiscoverySource:Insilico

Development

Salesandmarketing

BofAGLOBALRESEARCH

AI-drivensmartlaboratories

Drylab:usingcomputationalmodelsanddatatodecidewhattotest

Thedrylabisthecomputationalsideofdrugdiscovery.Itbringstogetherbiological,

chemicalandstructuraldatatogeneratehypothesesandprioritizewhatshouldbe

tested.Atthetargetstage,Alcananalyzeevidenceondiseasebiologytoidentify

potentialinterventionpoints.Atthemoleculestage,computationaltoolscanscreenorgeneratecandidatestructuresandpredictpropertiessuchastargetbinding,selectivity,ADMETandsyntheticfeasibility.Researchersusethesepredictionstoselectcompoundsforsynthesisandtodecidewhichpropertiestooptimizeinthenextdesigncycle.The

outputisthereforearankedsetofhypothesesandmoleculardesigns,notavalidateddrugcandidate.

Exhibit6:Drylabexample:avirtualcellmodel

AvirtualcellisacomputationalmodelofalivingcellThemodelpredictshowthecellresponds.

COMPOUNDPERTURBATION

Ilustrativesyntheticoutputfordesonstzaticn-notrealmodelpzedictions.It

mirrorstheclassofconditionalmut1-omtcsgenezationdescribedinthe

Source:Insilico

BofAGLOBALRESEARCH

Wetlab:runningphysicalexperimentstodeterminewhatactuallyhappens

Thewetlabconductsresearchthroughphysicalexperiments.Itsworkmayinclude

producingtargetproteins,synthesizingcompounds,measuringbindingandbiological

activity,assessingeffectsincells,andevaluatingandsafetyin

preclinicalmodels.Theseexperimentsestablishwhetheraproposedmoleculecanbe

madeandwhetheritsobservedpropertiessupportfurtheroptimization.Somestepscanbeautomated,butwet-labworkisnotsynonymouswithanautomatedlaboratory,sinceexperimentsmayalsobeperformedmanuallyorbyexternalresearchpartners.The

outputisexperimentalevidence,whichmayconfirmorchallengedry-labpredictions.

Closingtheloopbetweenpredictionandexperimentation

Generativemodelscandesignmoleculesrapidly,butthevalueofthosedesignsdependsonhowquicklytheycanbesynthesizedandtested.Withoutefficientlaboratory

validation,greatercomputationalspeedcouldsimplyshiftthebottleneckfrommoleculedesigntophysicalexperimentation.

AI-drivensmartlaboratoriesaddressthisbottleneckbyintegratingmoleculardesign,

compoundsynthesis,samplemanagement,cellculture,biologicalscreening,high-contentimaging,multi-omicsanalysisandexperimental-datainterpretation.Theiroperating

modelcanbesummarizedas:predict,design,synthesize,test,analyzeandredesign.AIfirstnarrowstherangeoftargetsormoleculesthatrequirephysicalinvestigation.Automatedequipmentthensynthesizesandteststheselectedcandidates,andthe

resultingdataarefedbackintothecomputationalplatformtoinformthenextdesigncycle.Theobjectiveisnottoeliminateexperimentsbuttoconductthemmore

selectively,consistentlyandrapidly.

Proprietaryexperimentaldatareinforcetheplatform

Closed-loopexperimentationgeneratesproprietarydataacrosstargetbiology,structure-activityrelationships,potency,selectivity,ADMET,animal,toxicity,

biomarkers,andclinicaloutcomes.Ifthesedataareconsistentlystructuredandfedbackintotheplatform,eachprogramcanpotentiallyimprovefuturemodelselectionand

candidatedesign.

Thiscreatesareinforcingflywheel.Moreprogramsgeneratemoreproprietary

experimentaldata,whichsupportbetterpredictionsanddecisionsandhigher-qualitycandidates.Thesecandidatesinturnbringadditionalclinicalandpartnershipvalidationandfurtherdatageneration.However,datavolumealonedoesnotcreateamoat.Thedatamustbehighquality,relevantacrossprogramsanddemonstratedtoimprove

prospectiveperformance.

Exhibit7:AI-drivensmartlaboratoriesdrugdiscoveryInnovationscanbecategorizedintofourkeyfunctionalareas

Keyarea

AIcapabilitiesandimpact

Automation

Automatedsystemsenhanceexperimentalprecisionandreliabilitybymaintainingcontrolledreactionconditionsandenablingcontinuousmonitoringoflaboratory

environments.TheresultingdatagenerationsupportsongoingoptimizationofR&Dprocessesandimprovesoverallefficiency.

Moleculedesignandsynthesis

AI-drivengenerativemodelsdesignnoveldrug-likemolecules,whicharesynthesized

throughautomatedplatformscapableofprocessinglargechemicallibraries.Thisiterativeprocessenablescontinuousrefinementofmolecularcandidatesbasedonexperimentaloutcomes.

Biologicaltestingand

Followingsynthesis,compoundsundergohigh-throughputbiologicalscreening,

supportedbyautomatedworkflowsthatgenerateandanalyzemulti-omicdata.Theseinsightsarefedbackintothediscoveryprocesstoimprovecandidateselectionand

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论